Michael Lattanzi

7PUBLICATIONS
45CO-AUTHORS
Cancer geneticsMolecular targetsOther chemical sciences not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 16, 2025
Quality of Informed Consent via Telemedicine Compared With In-Person for Clinical Cancer Research.

Michal Sternschuss, Michael Lattanzi, Emily Vertosick

|Sep 08, 2023
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.

Brendan J Guercio, Michal Sarfaty, Min Yuen Teo

|May 24, 2022
Reply to S. Zhang.

Michael Lattanzi, Samuel A Funt, Jonathan E Rosenberg

|Jan 28, 2022
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.

Samuel A Funt, Michael Lattanzi, Karissa Whiting

|Jun 20, 2020
The emerging role of antibody-drug conjugates in urothelial carcinoma.

Michael Lattanzi, Jonathan E Rosenberg

|Nov 09, 2019
Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.

Anna Pavlick, Ana B Blazquez, Marcia Meseck

Pageof 2

Frequent Collaborators

4 joint publications

Jonathan E Rosenberg

4 joint publications

Samuel A Funt

3 joint publications

Gopa Iyer

3 joint publications

Ashley Regazzi